Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer

British Journal of Pharmacology

Volumn 171, Issue 19, 2014, Pages 4464-4477

  Murase, Ryuichi ^a   Kawamura, Rumi ^a   Singer, Eric ^a   Pakdel, Arash ^a   Sarma, Pranamee ^a   Judkins, Jonathon ^a   Elwakeel, Eiman ^a   Dayal, Sonali ^a   Martinez Martinez, Esther ^a   Amere, Mukkanti ^b   Gujjar, Ramesh ^b   Mahadevan, Anu ^b   Desprez, Pierre Yves ^a   McAllister, Sean D ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b ORGANIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CANNABIDIOL; CANNABINOID; DICHLORODIHYDROFLUORESCEIN; INHIBITOR OF DIFFERENTIATION 1; O 1663; PROPIDIUM IODIDE; REACTIVE OXYGEN METABOLITE; RESORCINOL DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CANNABINOID 2 RECEPTOR; ID1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANNABIDIOL; CELL LINE, TUMOR; FEMALE; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB2; RESORCINOLS;

EID: 84927667530     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12803     Document Type: Article

References (48)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1562.
2. Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, Gonzalez-Feria L, et al. (2008). Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 68: 1945-1952.
3. Caffarel MM, Andradas C, Mira E, Perez-Gomez E, Cerutti C, Moreno-Bueno G, et al. (2010). Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9: 196.
4. Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G, et al. (2006a). Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66: 6748-6755.
5. Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V, et al. (2006b). The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9: 301-312.
6. Editorial (2011). Cancer drugs: remedy required. Nat Med 17: 231.
7. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443-450.
8. Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, et al. (2003). Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 100: 13543-13548.
9. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, et al. (2007). ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A 104: 19506-19511.
10. Hampson AJ, Grimaldi M, Axelrod J, Wink D, (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95: 8268-8273.
11. Hu H, Han HY, Wang YL, Zhang XP, Chua CW, Wong YC, et al. (2009). The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells. Oncol Rep 21: 1053-1059.
12. Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, Bennington JL, et al. (2003). Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res 63: 7098-7105.
13. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96: 14136-14141.
14. Kaplan BL, Springs AE, Kaminski NE, (2008). The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol 76: 726-737.
15. Kraljevic Pavelic S, Sedic M, Bosnjak H, Spaventi S, Pavelic K, (2011). Metastasis: new perspectives on an old problem. Mol Cancer 10: 22.
16. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
17. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387.
18. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97: 9561-9566.
19. Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, et al. (2010). Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180-189.
20. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D, (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838-845.
21. Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D, (2006). The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 63: 2057-2066.
22. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, et al. (2008). 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104: 1091-1100.
23. Mato S, Victoria Sanchez-Gomez M, Matute C, (2010). Cannabidiol induces intracellular calcium elevation and cytotoxicity in oligodendrocytes. Glia 58: 1739-1747.
24. McAllister SD, Tao Q, Barnett-Norris J, Buehner K, Hurst DP, Guarnieri F, et al. (2002). A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol 63: 2121-2136.
25. McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, et al. (2003). An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46: 5139-5152.
26. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY, (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6: 2921-2927.
27. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, et al. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129: 37-47.
28. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M, (2006). Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 70: 897-908.
30. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436 (7050): 518-524.
31. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, et al. (2005). Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36: 1077-1082.
32. Mo FM, Offertaler L, Kunos G, (2004). Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 489: 21-27.
33. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
34. Pertwee RG, (2006). Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 (Suppl. 1): S163-S171.
35. Ponz-Sarvise M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, et al. (2011). Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res 17: 4155-4166.
36. Ramer R, Merkord J, Rohde H, Hinz B, (2010). Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 79: 955-966.
37. Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, et al. (2012). Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 26: 1535-1548.
38. Russo EB, (2008). Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 4: 245-259.
39. 2+ levels. J Neurosci 29: 2053-2063.
40. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A, et al. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372.
41. Showalter VM, Compton DR, Martin BR, Abood ME, (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
42. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A, (2011). Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10: 1161-1172.
43. Swarbrick A, Roy E, Allen T, Bishop JM, (2008). Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci U S A 105: 5402-5407.
44. Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, et al. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10: 90-103.
45. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D, (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144: 1032-1036.
46. Velasco G, Sanchez C, Guzman M, (2012). Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12: 436-444.
47. Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, et al. (2002). Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther 301: 679-689.
48. Zuardi AW, (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271-280.